MARKET

PACB

PACB

Pacific Biosc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.17
+0.76
+14.05%
After Hours: 6.20 +0.03 +0.49% 19:59 05/27 EDT
OPEN
5.49
PREV CLOSE
5.41
HIGH
6.19
LOW
5.45
VOLUME
6.58M
TURNOVER
0
52 WEEK HIGH
36.36
52 WEEK LOW
4.510
MARKET CAP
1.38B
P/E (TTM)
-7.6163
1D
5D
1M
3M
1Y
5Y
Masayoshi Son is Selling These 9 Stocks in 2022
In this article, we discuss the 9 stocks Masayoshi Son is selling in 2022. If you wish to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Masayoshi Son is Selling These 4 Stocks in 2022. Masayoshi Son is the man behin...
Insider Monkey · 2d ago
Korean-Japanese Billionaire Masayoshi Son’s 2022 Portfolio: 10 Stocks to Watch
In this article, we discuss the 2022 portfolio of Korean-Japanese Billionaire Masayoshi Son and the 10 stocks to watch. If you want to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Korean-Japanese Billionaire Masayo...
Insider Monkey · 3d ago
PACB, JAMF and PRVB are among after hour movers
Gainers: O2Micro International Limited (OIIM) +20%. Fluence Energy (FLNC) +7%. Allarity Therapeutics (ALLR) +7%. SIGA Technologies (SIGA) +6%. Blackbaud (BLKB) +5%. Losers: Redbox Entertainment  (RDBX) -10%. Pacific Biosciences of California (PACB) -6%.
Seekingalpha · 05/20 21:58
Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know
Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over the last 24 hours, at $5.68 per share.
Benzinga · 05/16 16:01
--Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $6 From $13, Maintains Neutral Rating
MT Newswires · 05/16 08:03
Pacific Biosciences, iLAC, Robotic Biology Institute Enter Into Robotics Collaboration
MT Newswires · 05/09 04:38
PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows
Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read SequencingMENLO PARK, Calif., TOKYO, May 09, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly...
GlobeNewswire · 05/08 23:00
PacBio to Participate in the BofA Securities 2022 Healthcare Conference
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio’s management is scheduled to present on Thursday, May 12 at 11...
GlobeNewswire · 05/05 20:10
More
No Data
Learn about the latest financial forecast of PACB. Analyze the recent business situations of Pacific Biosc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
33.33%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PACB stock price target is 15.40 with a high estimate of 27.00 and a low estimate of 6.00.
High27.00
Average15.40
Low6.00
Current 6.17
EPS
Actual
Estimate
-0.28-0.18-0.090.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 331
Institutional Holdings: 238.26M
% Owned: 106.19%
Shares Outstanding: 224.38M
TypeInstitutionsShares
Increased
90
33.71M
New
41
7.91M
Decreased
67
15.51M
Sold Out
48
8.10M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+3.80%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Non-Executive Chairman/Independent Director
John Milligan
President/Chief Executive Officer/Director
Christian Henry
Chief Financial Officer
Susan Kim
Chief Operating Officer
Mark Van Oene
Senior Vice President
Catherine Ball
Senior Vice President
Denis Zaccarin
Chief Accounting Officer
Michele Farmer
General Counsel/Secretary
Brett Atkins
Independent Director
David Botstein
Independent Director
William Ericson
Independent Director
Randall Livingston
Independent Director
Marshall Mohr
Independent Director
Kathy Ordonez
Independent Director
Lucy Shapiro
Independent Director
Hannah Valantine
No Data
No Data
About PACB
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together are capable of sequencing up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together are capable of sequencing up to one million DNA molecules simultaneously. Its Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.

Webull offers kinds of Pacific Biosciences of California Inc stock information, including NASDAQ:PACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PACB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PACB stock methods without spending real money on the virtual paper trading platform.